This bill amends the Public Health Code by adding Section 17757c, which establishes new regulations for manufacturers, wholesalers, and wholesale distributor-brokers regarding the acquisition and delivery of 340B drugs. Specifically, it prohibits these entities from denying, restricting, or discriminating against 340B entities or authorized pharmacies in their ability to acquire or receive 340B drugs. However, exceptions are made if such actions are authorized by state or federal law.

Additionally, starting July 1, 2026, the bill mandates that 340B entities and manufacturers submit annual reports to the Department of Health and relevant legislative agencies. The reports from 340B entities must include details about their 340B program, compliance with audits, and the program's impact on patients and the community. Manufacturers are required to report on prescription drugs that exceed a specified cost and have seen significant price increases, including detailed information about the drug's pricing history and production costs. The Department is tasked with making these reports publicly accessible on its website.

Statutes affected:
Senate Introduced Bill: 333.1101, 333.25211
As Passed by the Senate: 333.1101, 333.25211